| 1 |
Preclinical Development of a UniStac®.based Long.acting Tetraspecific Drug for NASH |
| Recombinant Protein |
NASH |
FGF21,GLP.1,GCG,a.cytokine |
Preclinical |
Onegene Biotechnology Inc. |
RS-2023-00282937 |
|
| 2 |
Lead discovery and development of production process for
sarcopenia treatment NB-101 with NOTCH1 inhibitory mechanism |
| Recombinant Protein |
Sarcopenia |
NOTCH1 |
Lead |
NUON Bio |
RS-2022-00165803 |
|
| 3 |
Establishing of Fc-flagellin-based candidate drug (MSP-306) for NASH treatment and entering non-clinical trials |
| Recombinant Protein |
NASH |
TLR5 |
Candidate |
MediSpan |
HN22C0599 |
|
| 4 |
Pre-clinical study of YH34160 for obesity treatment |
| Recombinant Protein |
Obesity |
GDF15 |
Preclinical |
Yuhan |
HN22C0555 |
|
| 5 |
Exercise-induced myokine CLCF1, a novel potential treatment for sarcopenia |
| Recombinant Protein |
Sarcopenia |
CLCF1 |
Hit |
Korea Research Institute of Bioscience and Biotechnology |
HN22C0330 |
|
| 6 |
Global Clinical Trial and Commercialization for Development of Next-generation Long-acting Glucagon (HM15136 ) for Congenital Hyperinsulinism (CHI) |
| Recombinant Protein |
Congenital hyperinsulinism |
glucagon |
Phase 2 |
Hanmi Pharm. Co., Ltd. |
HN21C0601 |
|
| 7 |
Development of a preclinical candidate of a UniStac-based long-acting tetra-specific drug for NASH |
| Recombinant Protein |
NASH |
FGF21, GLP-1, GCG, a-cytokine |
Candidate |
Onegene Biotechnology Inc. |
HN21C0561 |
|
| 8 |
Development of long-acting human growth hormone receptor antagonist by next generation technology |
| Recombinant Protein |
Acromegaly |
hGH receptor |
Candidate |
Alteogen Inc. |
HN21C0535 |
|
